Excellent point. Fair Balance is the key to credibility. My assumption is that the company has provided me with a clinical paper or the published study where I can show the study design along with the actual SAE percentages and the reference to " not due to Leronlimab" and show that the comparison is apples to apples. The key message is Drug Safety only at this point. "Do no harm" I believe has been established. Once Safety is established on to the good stuff!!!